Description
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis.
Cat.No
A860
Name
Ixekizumab
Chemical Properties
CAS
1143503-69-8
Synonyms
Ixekizumab;Research Grade Ixekizumab(DHH28801);Research Grade Ixekizumab(DHH28801);Research Grade Ixekizumab(DHH28801);Research Grade Ixekizumab(DHH28801);Ixekizumab (anti-CTLA-8);Ixekizumab (anti-CTLA-8);Ixekizumab (anti-CTLA-8);Ixekizumab (anti-CTLA-8);LY2439821;LY2439821;LY2439821;LY2439821
pH value
Corresponds to reference standard: PASS
Non-reduced CE-SDS
>95%
SEC-HPLC
>95%
Isoelectric Point
Corresponds to reference standard
Bacterial Endotoxins Test
Residual Proteins of Host Cell
Exogenous Residual DNA
Residual protein A
Biological Activity
Osmolality
Corresponds to reference standard: PASS
Peptide mapping
Corresponds to reference standard: PASS
N-terminal sequence
Corresponds to reference standard: PASS
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131Fax: +86-21-61642470Email:
Website:
